Sanctuary Advisors LLC Sells 10,602 Shares of ASP Isotopes Inc. (NASDAQ:ASPI)

Sanctuary Advisors LLC trimmed its stake in shares of ASP Isotopes Inc. (NASDAQ:ASPI) by 44.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 13,040 shares of the company’s stock after selling 10,602 shares during the quarter. Sanctuary Advisors LLC’s holdings in ASP Isotopes were worth $59,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of ASPI. Hanson & Doremus Investment Management bought a new stake in shares of ASP Isotopes during the 4th quarter valued at $27,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of ASP Isotopes during the 3rd quarter worth $42,000. The Manufacturers Life Insurance Company bought a new stake in shares of ASP Isotopes during the 3rd quarter worth $52,000. JPMorgan Chase & Co. lifted its position in shares of ASP Isotopes by 31.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,196 shares of the company’s stock worth $62,000 after buying an additional 5,307 shares during the last quarter. Finally, KKM Financial LLC lifted its position in shares of ASP Isotopes by 66.2% during the 3rd quarter. KKM Financial LLC now owns 22,600 shares of the company’s stock worth $63,000 after buying an additional 9,000 shares during the last quarter. 16.80% of the stock is currently owned by institutional investors.

ASP Isotopes Price Performance

Shares of ASPI stock opened at $4.06 on Friday. The company has a quick ratio of 7.54, a current ratio of 7.55 and a debt-to-equity ratio of 0.80. ASP Isotopes Inc. has a twelve month low of $1.86 and a twelve month high of $9.33. The company has a market cap of $289.84 million, a P/E ratio of -6.66 and a beta of 3.51. The business has a fifty day simple moving average of $5.24 and a 200 day simple moving average of $4.70.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.